Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors
BOSTON , July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the
View HTML
Toggle Summary Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma
BOSTON , June 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled IL-12) in combination with the PD-1 inhibitor Libtayo
View HTML
Toggle Summary Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board
BOSTON , June 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl June , M.D., as Chairman of its newly formed Scientific Advisory Board (SAB). Dr.
View HTML
Toggle Summary Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020
BOSTON , June 12, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a webcast panel session titled Cell Therapy : Promise of the Next Generation at the Raymond
View HTML
Toggle Summary Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology
  – Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile –   – Controlled IL-12 in combination with PD-1 inhibitor has favorable safety profile and initial survival data are encouraging – – Data again consistent
View HTML
Toggle Summary Ziopharm Oncology Announces Management Transition
Dr. David Mauney stepping down as President; Remains a consultant to the Company BOSTON , May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced Dr. David Mauney is stepping down as President. Dr.
View HTML
Toggle Summary Ziopharm Oncology to Present at the Jefferies 2020 Healthcare Conference on June 3, 2020
BOSTON , May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a virtual fireside chat at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 ,
View HTML
Toggle Summary Ziopharm Oncology to Present at the BofA Securities 2020 Health Care Conference
BOSTON , May 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 , at
View HTML
Toggle Summary Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update
– Regulatory discussions with FDA advance Ziopharm TCR-T IND process – – Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® ; Controlled IL-12 clinical data update at ASCO 2020 – – Work restrictions at NCI and MD Anderson impacting clinical trials; Ziopharm
View HTML
Toggle Summary Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting
BOSTON , April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the treatment
View HTML